NASDAQ$ALT
Altimmune Inc · Q4 2024 earnings
Q4 2024 earnings · · Before market open · Investor relations
Briefing
Altimmune reported its Q4 2024 financial results and provided a business update.
Altimmune reported a net loss of $23.2 million for the fourth quarter of 2024, with cash, cash equivalents, and short-term investments totaling $131.9 million as of December 31, 2024. The company is advancing pemvidutide in multiple indications and expects to report top-line data from the Phase 2b IMPACT trial in Q2 2025.
- IMPACT Phase 2b trial of pemvidutide in MASH is on track to report top-line data in Q2 2025.
- IND applications for pemvidutide in two additional indications have been cleared by the FDA, with Phase 2 trials expected to commence mid-2025.
- Altimmune will hold a virtual R&D Day on March 13, 2025, to discuss pemvidutide development in obesity, MASH, and additional indications.
- The company's Board of Directors was strengthened with the addition of two pharmaceutical industry veterans.
Headline financials
Revenue & EPS history
Altimmune · Revenue · Quarterly
$5K
Forward guidance
Altimmune is focused on advancing pemvidutide in multiple indications. Top-line data from the Phase 2b IMPACT trial in MASH is expected in Q2 2025, and Phase 2 trials in two additional indications are planned to commence mid-2025.
Tailwinds
- Top-line data from Phase 2b IMPACT trial of pemvidutide in MASH to be reported in Q2 2025.
- IND applications in two additional indications have received FDA clearance, with Phase 2 trials to commence mid-2025.
- Company to hold virtual R&D Day on March 13, 2025.
- Pemvidutide has the potential to achieve statistically significant improvements in biopsy endpoints.
- FDA Fast Track designation granted to pemvidutide for the treatment of MASH.
Headwinds
- Forward-looking statements are subject to numerous assumptions, risks, and uncertainties.
- Delays in regulatory review could impact timelines.
- Manufacturing and supply chain interruptions may occur.
- Access to clinical sites and enrollment could face challenges.
- Adverse effects on healthcare systems and disruption of the global economy could affect results.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q4 2024
+2.4%
Avg return
Earnings day
+1.5%
Avg return
5 days after
+5.6%
Avg return
30 days after
60%
21 / 35 earnings
Positive
+35.0%
Q2 2022
Best reaction
-25.1%
Q3 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2026 | -2.0% | -8.8% | -15.3% | |
| Q4 2025 | -17.6% | -9.6% | -21.8% | |
| Q3 2025 | +5.1% | +14.1% | +39.7% | |
| Q1 2025 | -4.2% | -7.2% | +19.0% | |
| Q4 2024 | +8.1% | +0.3% | -10.4% | |
| Q3 2024 | +29.5% | +3.5% | +16.9% | |
| Q2 2024 | +12.2% | +14.7% | +12.7% | |
| Q1 2024 | +0.8% | +9.2% | -9.8% | |
| Q4 2023 | +17.7% | +18.3% | -16.1% | |
| Q3 2023 | +1.1% | -6.4% | +146.4% | |
| Q2 2023 | +2.0% | -4.7% | -16.9% | |
| Q1 2023 | +2.2% | -6.6% | -19.7% | |
| Q4 2022 | +1.9% | -2.0% | -64.3% | |
| Q3 2022 | +10.3% | +12.7% | +4.2% | |
| Q2 2022 | +35.0% | +37.3% | +55.4% | |
| Q1 2022 | +31.0% | +34.3% | +117.0% | |
| Q4 2021 | +2.2% | +12.1% | -18.7% | |
| Q3 2021 | -0.5% | +1.3% | -12.3% | |
| Q2 2021 | +6.6% | +14.9% | +56.8% | |
| Q1 2021 | +5.2% | +4.7% | +23.0% | |
| Q4 2020 | -18.6% | -19.5% | -29.3% | |
| Q3 2020 | -25.1% | -18.6% | -1.1% | |
| Q2 2020 | -13.5% | -5.5% | -54.3% | |
| Q1 2020 | +21.4% | +21.6% | +103.8% | |
| Q4 2019 | -7.1% | -6.5% | -2.8% | |
| Q3 2019 | -8.0% | -10.9% | -1.7% | |
| Q2 2019 | -6.5% | -6.5% | -0.9% | |
| Q1 2019 | +2.7% | -4.7% | -3.5% | |
| Q4 2018 | +3.4% | +6.6% | -0.7% | |
| Q3 2018 | -6.8% | -9.1% | -31.5% | |
| Q2 2018 | +4.9% | +0.3% | -21.0% | |
| Q1 2018 | +10.8% | -1.9% | +1.7% | |
| Q4 2017 | -8.3% | -5.9% | -36.0% | |
| Q3 2017 | -1.0% | -7.1% | -25.1% | |
| Q2 2017 | -10.3% | -12.0% | +11.6% | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q3 2012 | — | — | — | |
| Q2 2012 | — | — | — | |
| Q1 2011 | — | — | — | |
| Q1 2012 | — | — | — | |
| Q4 2011 | — | — | — | |
| Q3 2011 | — | — | — | |
| Q2 2011 | — | — | — | |
| Q4 2010 | — | — | — | |
| Q3 2010 | — | — | — | |
| Q2 2010 | — | — | — | |
| Q1 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro